Table 1 Clinical and laboratory features of myeloproliferative neoplasm (MPN) patients used for two-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry (MS) assays

Patients

10

10

Gender (M/F)

5/5

3/7

Age at diagnosis^a

68 (60–84)

38 (34–56)

Splenomegaly at diagnosis

0/10

1/10

Hepatomegaly at diagnosis

0/10

1/10

Hemoglobin (g/100 mL) at diagnosis^a

18.3 (17.4-20.3)

14.95 (12.6-16.9)

Hematocrit at diagnosis^a

58.25 (51–62.5)

45,52 (37.4-49,7)

WBC (x10⁹/L) at diagnosis^a

10.65 (3.94-16.15)

12.1 (8.1-14.5)

Platelets (x10⁹/L) at diagnosis^a

371 (168–394)

615.5 (564–657)

Increased LDH at diagnosis

3/10

1/10

Thrombotic events at diagnosis

1/10

0/10

Hemorrhagic events at diagnosis

0/10

0/10

Thrombotic events after diagnosis

1/10

0/10

Hemorrhagic events after diagnosis

0/10

0/10

Response to treatment

3/6

1/10

Disease duration (in months)

55.5 (14–179)

92.5 (13–100)

Treatment duration (in months)^a

7 (0–179)

0 (0–86)